Angimil SR Tablet

Brand Name: Angimil SR
Generic: Verapamil Hydrochloride
Weight: 240 mg
Type: Tablet
Therapeutic Class: Calcium-channel blockers
Manufacturer: Medimet Pharmaceuticals Ltd.
Price: 9.80
Last Updated: 2020-11-20 18:15:00

Angimil SR Tablet Uses

Angimil SR Tablet contains Verapamil Hydrochloride. Angimil SR uses:

Verapamil Tablet:

  • Essential hypertension
  • Angina pectoris and prevention of re-infarction
  • Supraventricular arrhythmias

Verapamil Injection:

  • Tachycardias such as: Paroxysmal supraventricular tachycardias
  • Atrial fibrillation with rapid ventricular response (except WPWS)
  • Atrial flutter with rapid conduction
  • Extrasystoles
  • Acute hypertension
  • Acute coronary insufficiency

For the prophylaxis and / or therapy of ectopic arrhythmias (predominantly ventricular extrasystoles) in halothane anaesthesia and in the application of adrenaline in halothane anaesthesia respectively.

Angimil SR Tablet Doses

Angimil SR Tablet contains Verapamil Hydrochloride 240 mg. Angimil SR doses:

Verapamil Tablet:

  • The dose of Verapamil should be individualized by titration and the drug should be administered with food.
  • For essential hypertension the initial dose should be given 180 mg in the morning. If  adequate response is not obtained with 180 mg of Verapamil then the dose may be titrated by following manner: 240 mg each morning. 180 mg each morning plus 180 mg each evening. 240 mg every 12 hourly.
  • For angina the usual dose is 80 mg to 120 mg three times a day.
  • For arrythmias in digitalized patients, Verapamil should be given 240 mg to 360 mg in divided doses, depending on the severity of the condition. Divided doses up to 180 mg/day may occasionally be needed.

Verapamil Injection:


: 5 mg slowly intravenously, in tachycardias and hypertensive crises, if necessary repeat after 5 to 10 minutes. Drip infusion to maintain the therapeutic effect: 5-10 mg/hour in physiological saline, glucose, laevulose or similar solutions, on average up to a total dose of 100 mg/day. 



  • Newborn: 0.75-1 mg (= 0.3-0.4 ml)
  • Infants: 0.75-2 mg (= 0.3-0.8 ml)
  • Children age 1-5 years: 2-3 mg (= 0.8-1.2 ml)
  • Age 6-14 years: 2.5-5 mg (= 1-2 ml)

of Verapamil, given intravenously, depending on age and action. The injection should be made slowly under electrocardiographic control and only until onset of the effect. Intravenous infusion in hypertensive crises: initially 0.05-0.1 mg/kg/hour; if the effect proves to be insufficient, the dose is increased at 30-60 minute intervals until twice the dose or more is reached. Average total dose up to 1.5 mg/kg/day.


Side Effects

Verapamil is generally well tolerated. The following reaction to orally administered Verapamil appeared clearly drug related or occurred at rates greater than 1% in clinical trials with approximately 5000 patients.

  • Digestive system: Constipation, nausea;
  • Cardiovascular system: Hypotension, edema, CHF, pulmonary edema, bradycardia, AV block;
  • Respiratory system: Upper respiratory tract infections;
  • Nervous system: Dizziness, headache, fatigue;
  • Skin: Rash, flashing;
  • Hepatic: Elevated liver enzyme.

Verapamil inhibits entry of Ca ions into the slow channels or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarisation. It relaxes coronary vascular smooth muscle and coronary vasodilation, increases myocardial oxygen delivery, and slows automaticity and AV node conduction.

Angimil SR Precaution

Care should be taken in 1st degree AV block, bradycardia <50 beats/minutes, hypotension <90 mm Hg systolic pressure, atrial fibrillation/flutter and simultaneous pre-excitation syndrome e.g. WPW syndrome, heart failure (previous compensation with cardiac glycosides/diuretics required).Verapamil may impair ability to drive or operate machinery, particularly in the initial stages of treatment and with concomitant consumption of alcohol. Verapamil markedly slows down the elimination of alcohol and prolongs the duration of the effects of alcohol.Verapamil should be given as a slow intravenous injection over at least 2 minutes under continuous ECG and blood pressure monitoring. Intravenous injection should only be given by the physician. In atrial fibrillation and simultaneous WPW syndrome there is a risk of inducing ventricular fibrillation


May increase plasma level with CYP3A4 inhibitors (e.g. erythromycin, ritonavir), cimetidine. May decrease plasma level with CYP3A4 inducers (e.g. rifampicin), phenobarbital, sulfinpyrazone. Increased risk of bleeding with aspirin. May increase bradycardic and hypotensive effect with telithromycin. Increased AV blocking effect with clonidine. May increase plasma level of cardiac glycosides (e.g. digoxin, digitoxin), β-blockers (e.g. propranolol, metoprolol), α-blockers (e.g. terazosin, prazosin), immunosuppressants (e.g. sirolimus, ciclosporin, tacrolimus, everolimus), lipid lowering agents (e.g. lovastatin, simvastatin, atorvastatin), colchicines, quinidine, carbamazepine, imipramine, glibenclamide, doxorubicin, midazolam, buspirone, almotriptan, theophylline. May potentiate hypotensive effect with diuretics, antihypertensives, vasodilators. May increase neurotoxic effect of lithium.

Pregnancy Lactation use

Verapamil carries the potential to produce fetal hypoxia associated with maternal hypotension. Verapamil should not be administered intravenously during the first six months of pregnancy. There are no data on use in the first and second trimester. Verapamil should not be used in the final trimester unless the benefits clearly outweigh the risks. Verapamil should not be administered intravenously during lactation. If a nursing mother requires intravenous Verapamil, breast feeding should be discontinued for the duration of treatment.

  • Severe left ventricular dysfunction
  • Hypotension or cardiogenic shock
  • Sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker)
  • Second or third-degree atrioventricular (AV) block (except in patients with a functioning artificial pacemaker)
  • Patients with atrial flutter or atrial fibrillation and an accessory by pass tract (eg. Wolff-Parkinson-White, Lown-Ganong-Levine syndrome)
  • Patients with known hypersensitivity to verapamil hydrochloride
  • Verapamil injection should not be administered intravenously to patients on beta-blockers (except in an intensive care setting) and known hypersensitivity to Verapamil hydrochloride.
Special Warning


Acute Overdose

Treatment of overdose should be supportive. Beta-adrenergic stimulation or parenteral administration of calcium solution may increase calcium ion flux across the slow channel and have been used in the treatment of overdose with Verapamil. Verapamil cannot be removed by haemodialysis.

Interaction with other Medicine


Storage Condition


Angimil SR Tablet price in Bangladesh 9.80